• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form D filed by AN2 Therapeutics Inc.

    3/25/26 4:42:23 PM ET
    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ANTX alert in real time by email
    Form D
    FORM D
    Notice of Exempt Offering of Securities

    UNITED STATES SECURITIES
    AND EXCHANGE COMMISSION
    Washington, D.C.

    OMB APPROVAL
    OMB Number: 3235-0076
    Estimated Average burden hours per response: 4.0
    1. Issuer's Identity
    CIK (Filer ID Number)Previous Name(s)Checkbox checkedNoneEntity Type
    0001880438
    Radio button checkedCorporation
    Radio button not checked Limited Partnership
    Radio button not checked Limited Liability Company
    Radio button not checked General Partnership
    Radio button not checked Business Trust
    Radio button not checkedOther 
    Name of Issuer
     AN2 Therapeutics, Inc.
    Jurisdiction of Incorporation/Organization
    DELAWARE 
    Year of Incorporation/Organization
    Radio button checkedOver Five Years Ago
    Radio button not checkedWithin Last Five Years (Specify Year)
     
    Radio button not checkedYet to Be Formed
     
      
      
     
    2. Principal Place of Business and Contact Information
    Name of Issuer
     AN2 Therapeutics, Inc.
    Street Address 1Street Address 2
     1300 EL CAMINO REAL, SUITE 100
     
    CityState/Province/CountryZIP/Postal CodePhone No. of Issuer
     MENLO PARK
     CALIFORNIA
     
     94025
     (650) 331-9090 




    3. Related Persons

    Last NameFirst NameMiddle Name
    Easom
    Eric
    Street Address 1Street Address 2
     c/o AN2 Therapeutics, Inc. 
     1300 EL CAMINO REAL, SUITE 100
    CityState/Province/CountryZIP/Postal Code
     MENLO PARK
     CALIFORNIA
     94025
     
    Relationship:Checkbox checkedExecutive OfficerCheckbox checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)
     



    Last NameFirst NameMiddle Name
    Eizen
    Joshua
    Street Address 1Street Address 2
     c/o AN2 Therapeutics, Inc. 
     1300 EL CAMINO REAL, SUITE 100
    CityState/Province/CountryZIP/Postal Code
     MENLO PARK
     CALIFORNIA
     94025
     
    Relationship:Checkbox checkedExecutive OfficerCheckbox not checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)
     



    Last NameFirst NameMiddle Name
    Day
    Lucy
    Street Address 1Street Address 2
     c/o AN2 Therapeutics, Inc. 
     1300 EL CAMINO REAL, SUITE 100
    CityState/Province/CountryZIP/Postal Code
     MENLO PARK
     CALIFORNIA
     94025
     
    Relationship:Checkbox checkedExecutive OfficerCheckbox not checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)
     



    Last NameFirst NameMiddle Name
    Chanda
    Sanjay
    Street Address 1Street Address 2
     c/o AN2 Therapeutics, Inc. 
     1300 EL CAMINO REAL, SUITE 100
    CityState/Province/CountryZIP/Postal Code
     MENLO PARK
     CALIFORNIA
     94025
     
    Relationship:Checkbox checkedExecutive OfficerCheckbox not checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)
     



    Last NameFirst NameMiddle Name
    Zakrzewski
    Joseph
    S.
    Street Address 1Street Address 2
     c/o AN2 Therapeutics, Inc. 
     1300 EL CAMINO REAL, SUITE 100
    CityState/Province/CountryZIP/Postal Code
     MENLO PARK
     CALIFORNIA
     94025
     
    Relationship:Checkbox not checkedExecutive OfficerCheckbox checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)
     



    Last NameFirst NameMiddle Name
    Aziz
    Kabeer
    Street Address 1Street Address 2
     c/o AN2 Therapeutics, Inc. 
     1300 EL CAMINO REAL, SUITE 100
    CityState/Province/CountryZIP/Postal Code
     MENLO PARK
     CALIFORNIA
     94025
     
    Relationship:Checkbox not checkedExecutive OfficerCheckbox checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)
     



    Last NameFirst NameMiddle Name
    Readnour
    Rob
    Street Address 1Street Address 2
     c/o AN2 Therapeutics, Inc. 
     1300 EL CAMINO REAL, SUITE 100
    CityState/Province/CountryZIP/Postal Code
     MENLO PARK
     CALIFORNIA
     94025
     
    Relationship:Checkbox not checkedExecutive OfficerCheckbox checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)
     



    Last NameFirst NameMiddle Name
    Marks
    Gilbert
    Lynn
    Street Address 1Street Address 2
     c/o AN2 Therapeutics, Inc. 
     1300 EL CAMINO REAL, SUITE 100
    CityState/Province/CountryZIP/Postal Code
     MENLO PARK
     CALIFORNIA
     94025
     
    Relationship:Checkbox not checkedExecutive OfficerCheckbox checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)
     



    Last NameFirst NameMiddle Name
    Wong
    Stephanie
    Street Address 1Street Address 2
     c/o AN2 Therapeutics, Inc. 
     1300 EL CAMINO REAL, SUITE 100
    CityState/Province/CountryZIP/Postal Code
     MENLO PARK
     CALIFORNIA
     94025
     
    Relationship:Checkbox not checkedExecutive OfficerCheckbox checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)
     



    Last NameFirst NameMiddle Name
    Martin
    Patricia
    Street Address 1Street Address 2
     c/o AN2 Therapeutics, Inc. 
     1300 EL CAMINO REAL, SUITE 100
    CityState/Province/CountryZIP/Postal Code
     MENLO PARK
     CALIFORNIA
     94025
     
    Relationship:Checkbox not checkedExecutive OfficerCheckbox checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)
     



    Last NameFirst NameMiddle Name
    Spigelman
    Melvin
    Street Address 1Street Address 2
     c/o AN2 Therapeutics, Inc. 
     1300 EL CAMINO REAL, SUITE 100
    CityState/Province/CountryZIP/Postal Code
     MENLO PARK
     CALIFORNIA
     94025
     
    Relationship:Checkbox not checkedExecutive OfficerCheckbox checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)
     



    Last NameFirst NameMiddle Name
    FitzPatrick
    Margaret
    Street Address 1Street Address 2
     c/o AN2 Therapeutics, Inc. 
     1300 EL CAMINO REAL, SUITE 100
    CityState/Province/CountryZIP/Postal Code
     MENLO PARK
     CALIFORNIA
     94025
     
    Relationship:Checkbox not checkedExecutive OfficerCheckbox checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)
     





    4. Industry Group
     Radio button not checkedAgriculture
    Banking & Financial Services
     Radio button not checked Commercial Banking
     Radio button not checked Insurance
     Radio button not checkedInvesting
     Radio button not checked Investment Banking
     Radio button not checked Pooled Investment Fund

     Radio button not checkedOther Banking & Financial Services
    Radio button not checked Business Services
    Energy
     Radio button not checked Coal Mining
     Radio button not checked Electric Utilities
     Radio button not checked Energy Conservation
     Radio button not checked Environmental Services
     Radio button not checked Oil & Gas
     Radio button not checked Other Energy
    Health Care
     Radio button not checked Biotechnology
     Radio button not checked Health Insurance
     Radio button not checked Hospitals & Physicians
     Radio button checked Pharmaceuticals
     Radio button not checked Other Health Care
       
       
       
      
    Radio button not checked Manufacturing
    Real Estate
     Radio button not checkedCommercial
     Radio button not checkedConstruction
     Radio button not checkedREITS & Finance
     Radio button not checkedResidential
    Radio button not checkedOther Real Estate
    Radio button not checked Retailing
    Radio button not checkedRestaurants
    Technology
    Radio button not checked Computers
    Radio button not checked Telecommunications
    Radio button not checked Other Technology
    Travel
    Radio button not checked Airlines & Airports
    Radio button not checked Lodging & Conventions
    Radio button not checked Tourism & Travel Services
    Radio button not checked Other Travel
    Radio button not checkedOther

      
       
    5. Issuer Size
    Revenue RangeAggregate Net Asset Value Range
    Radio button not checkedNo RevenuesRadio button not checked No Aggregate Net Asset Value
    Radio button not checked $1 - $1,000,000Radio button not checked$1 - $5,000,000
    Radio button not checked $1,000,001 - $5,000,000Radio button not checked $5,000,001 - $25,000,000
    Radio button not checked$5,000,001 - $25,000,000Radio button not checked $25,000,001 - $50,000,000
    Radio button not checked$25,000,001 - $100,000,000Radio button not checked $50,000,001 - $100,000,000
    Radio button not checked Over $100,000,000Radio button not checked Over $100,000,000
    Radio button checked Decline to Disclose Radio button not checkedDecline to Disclose
    Radio button not checked Not ApplicableRadio button not checked Not Applicable

     
    6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)
    Checkbox not checkedRule 504(b)(1) (not (i), (ii)
    or (iii))
    Checkbox checkedRule 506(b)      
    Checkbox not checkedRule 504 (b)(1)(i) Checkbox not checkedRule 506(c)
    Checkbox not checkedRule 504 (b)(1)(ii) Checkbox not checkedSecurities Act Section 4(a)(5)
    Checkbox not checkedRule 504 (b)(1)(iii)Checkbox not checkedInvestment Company Act Section 3(c)
     
     

    7. Type of Filing
    Checkbox checked New Notice Date of First Sale 
    2026-03-10
    Checkbox not checked First Sale Yet to Occur
    Checkbox not checked Amendment


     
     
    8. Duration of Offering
    Does the Issuer intend this offering to last more than one year? Radio button not checked Yes Radio button checked No
     
     
    9. Type(s) of Securities Offered (select all that apply)
    Checkbox not checkedPooled Investment Fund InterestsCheckbox checkedEquity
    Checkbox not checkedTenant-in-Common Securities Checkbox not checkedDebt
    Checkbox not checkedMineral Property SecuritiesCheckbox checkedOption, Warrant or Other Right to Acquire Another Security
    Checkbox checkedSecurity to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire SecurityCheckbox not checkedOther (describe)
     
     
     
    10. Business Combination Transaction
    Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer? Radio button not checked Yes Radio button checked No
    Clarification of Response (if Necessary)
     
     
     
    11. Minimum Investment
    Minimum investment accepted from any outside investor$
     0
    USD

    12. Sales Compensation
    Recipient Recipient CRD NumberCheckbox not checkedNone
     Leerink Partners LLC
     39011
    (Associated) Broker or DealerCheckbox checkedNone(Associated) Broker or Dealer CRD Number Checkbox checkedNone
      
      
    Street Address 1      Street Address 2
    53 STATE STREET
    40TH FLOOR
    City State/Province/CountryZIP/Postal Code
     BOSTON
     MASSACHUSETTS
     02109
    State(s) of SolicitationCheckbox not checkedAll StatesCheckbox not checkedForeign/Non-US
     
    ALABAMA
    ALASKA
    ARIZONA
    ARKANSAS
    CALIFORNIA
    COLORADO
    CONNECTICUT
    DELAWARE
    DISTRICT OF COLUMBIA
    FLORIDA
    GEORGIA
    HAWAII
    IDAHO
    ILLINOIS
    INDIANA
    IOWA
    KANSAS
    KENTUCKY
    LOUISIANA
    MAINE
    MARYLAND
    MASSACHUSETTS
    MICHIGAN
    MINNESOTA
    MISSISSIPPI
    MISSOURI
    MONTANA
    NEBRASKA
    NEVADA
    NEW HAMPSHIRE
    NEW JERSEY
    NEW MEXICO
    NEW YORK
    NORTH CAROLINA
    NORTH DAKOTA
    OHIO
    OKLAHOMA
    OREGON
    PENNSYLVANIA
    RHODE ISLAND
    SOUTH CAROLINA
    SOUTH DAKOTA
    TENNESSEE
    TEXAS
    UTAH
    VERMONT
    VIRGINIA
    WASHINGTON
    WEST VIRGINIA
    WISCONSIN
    WYOMING




    13. Offering and Sales Amounts
     
    Total Offering Amount $
    39999989
    USDCheckbox not checkedIndefinite
    Total Amount Sold $
    39999989
    USD
    Total Remaining to be Sold $
    0
    USDCheckbox not checkedIndefinite
    Clarification of Response (if Necessary)
      
     
    14. Investors

    Checkbox not checkedSelect if securities in the offering have been or may be sold to persons who do not qualify as accredited investors,
    Number of such non-accredited investors who already have invested in the offering
       
      Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:
    16
     
    15. Sales Commissions & Finders’ Fees Expenses
    Provide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.
    Sales Commissions$
    2400003
    USDCheckbox not checkedEstimate
    Finders' Fees$
    0
    USDCheckbox not checkedEstimate
    Clarification of Response (if Necessary)
     
     

    16. Use of Proceeds
    Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.
     $ 
    0
    USDCheckbox not checkedEstimate
    Clarification of Response (if Necessary)
     

    Signature and Submission
     
    Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.
    Terms of Submission 
     In submitting this notice, each Issuer named above is: 
     
    • Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, the information furnished to offerees.
    • Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the Issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against it in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of:  (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
    • Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).
     
    Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.
    For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.
     
    IssuerSignatureName of SignerTitleDate
    AN2 Therapeutics, Inc./s/ Eric EasomEric EasomChief Executive Officer2026-03-24




    Get the next $ANTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ANTX

    DatePrice TargetRatingAnalyst
    8/9/2024In-line → Underperform
    Evercore ISI
    8/9/2024$5.00 → $1.00Outperform → Market Perform
    Leerink Partners
    7/3/2024$5.00Market Perform → Outperform
    Leerink Partners
    4/2/2024$6.00Mkt Perform → Mkt Outperform
    JMP Securities
    2/13/2024$23.00 → $7.00Outperform → Market Perform
    Leerink Partners
    2/12/2024$25.00 → $7.00Outperform → In-line
    Evercore ISI
    2/12/2024Outperform → Perform
    Oppenheimer
    2/12/2024Mkt Outperform → Mkt Perform
    JMP Securities
    More analyst ratings

    $ANTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Easom Eric bought $10,665 worth of shares (10,000 units at $1.07), increasing direct ownership by 4% to 256,380 units (SEC Form 4)

    4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)

    6/3/25 4:46:15 PM ET
    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Fitzpatrick Margaret M bought $10,133 worth of shares (8,610 units at $1.18) (SEC Form 4)

    4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)

    5/29/25 4:17:48 PM ET
    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Readnour Robin Shane bought $86,708 worth of shares (60,000 units at $1.45) (SEC Form 4)

    4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)

    12/10/24 8:46:19 PM ET
    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Day Lucy

    4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)

    3/23/26 7:16:42 PM ET
    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chanda Sanjay

    4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)

    3/23/26 7:16:39 PM ET
    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Marks Gilbert Lynn

    4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)

    3/23/26 7:13:56 PM ET
    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANTX
    SEC Filings

    View All

    SEC Form D filed by AN2 Therapeutics Inc.

    D - AN2 Therapeutics, Inc. (0001880438) (Filer)

    3/25/26 4:42:23 PM ET
    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by AN2 Therapeutics Inc.

    8-K - AN2 Therapeutics, Inc. (0001880438) (Filer)

    3/20/26 4:37:10 PM ET
    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by AN2 Therapeutics Inc.

    S-8 - AN2 Therapeutics, Inc. (0001880438) (Filer)

    3/17/26 4:10:15 PM ET
    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    AN2 Therapeutics downgraded by Evercore ISI

    Evercore ISI downgraded AN2 Therapeutics from In-line to Underperform

    8/9/24 8:39:40 AM ET
    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AN2 Therapeutics downgraded by Leerink Partners with a new price target

    Leerink Partners downgraded AN2 Therapeutics from Outperform to Market Perform and set a new price target of $1.00 from $5.00 previously

    8/9/24 7:16:36 AM ET
    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AN2 Therapeutics upgraded by Leerink Partners with a new price target

    Leerink Partners upgraded AN2 Therapeutics from Market Perform to Outperform and set a new price target of $5.00

    7/3/24 7:25:34 AM ET
    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    AN2 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business and Scientific Highlights

    Phase 2 study of oral epetraborole in polycythemia vera (PV) expected to begin 3Q26 with potential for data readouts as early as 4Q26 and throughout 2027 Advancing Phase 2 investigator-initiated trial of epetraborole in M. abscessus complex lung disease; Enrollment expected to begin in 1Q26 with topline results anticipated in late 2027 Chagas disease program progresses as Phase 1 first-in-human trial of oral AN2-502998 nears completion with initial clinical data expected in 1Q26; Initiation of Phase 2 proof-of-concept study in patients with chronic Chagas disease planned for 2026 pending results On track to advance two boron-based oncology compounds into development in 2026 March 20

    3/17/26 4:00:00 PM ET
    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AN2 Therapeutics Announces $40 Million Private Placement Financing

    AN2 Therapeutics, Inc. (NASDAQ:ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that it has entered into a securities purchase agreement for a private placement that is expected to result in gross proceeds of approximately $40 million, before deducting placement agent fees and other expenses. The private placement includes participation from Coastlands Capital, Commodore Capital, Vivo Capital and other new and existing institutional investors. In the private placement, AN2 Therapeutics is selling 8,245,611 shares of common stock at a price of $2.85 per share and, in lieu of common stoc

    3/9/26 7:00:00 AM ET
    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AN2 Therapeutics Announces Plans to Advance Oral Epetraborole into Phase 2 Study for Polycythemia Vera (PV)

    Substantial clinical evidence provides rationale to initiate Phase 2 study in PV Phase 2 study expected to begin 3Q26 with potential for data readouts as early as 4Q26 and throughout 2027 AN2 to host webcast on Wednesday, March 4, 2026 at 9:30am ET/ 6:30am PT AN2 Therapeutics, Inc. (NASDAQ:ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced its plans to expand the development of oral epetraborole into a Phase 2 proof-of-concept clinical study in adults with phlebotomy-dependent polycythemia vera (PV). PV is a blood cancer characterized by overproduction of red blood cells in the bone

    3/3/26 4:00:00 PM ET
    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANTX
    Financials

    Live finance-specific insights

    View All

    AN2 Therapeutics Adopts Limited Duration Stockholder Rights Plan

    AN2 Therapeutics, Inc. (NASDAQ:ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that it has adopted a limited duration stockholder rights plan, which is scheduled to expire on August 15, 2025. The Company recently became aware of the rapid accumulation of a significant amount (19.3%) of the common stock of the Company by BML Investment Partners, L.P. (BML), as disclosed in a Schedule 13G/A filed with the U.S. Securities and Exchange Commission (SEC) on August 14, 2024. The Board of Directors believes that the rights plan will help promote the fair and equal treatment of all

    8/16/24 7:00:00 AM ET
    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific Highlights

    Phase 2/3 trial (EBO-301) in treatment-refractory Mycobacterium avium Complex (TR-MAC) continues with Phase 2 topline results expected in summer 2024 and Phase 3 enrollment pause in place during continued analysis of incoming data; plan to discuss with FDA Cash, cash equivalents, and investments of $134.5 million at December 31, 2023 AN2 Therapeutics, Inc. (NASDAQ:ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the fourth quarter and year ended December 31, 2023. "AN2's cash position remains strong as we advance our innovative boron-based pi

    3/28/24 4:10:00 PM ET
    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results

    Transitioning HBV cure programs into multiple late-stage combination studies with interim results throughout 2024 and 2025 informing Company's registrational strategy Integrating R&D, manufacturing and commercial upsides by acquiring full intellectual property rights of BRII-179 and expanding its manufacturing footprint Prioritizing company resources with a robust cash balance of US$376 million supporting operations until 2027 Company to host a conference call (English session) on March 25 at 8:30 AM ET / 8:30 PM HKT DURHAM, N.C. and BEIJING, March 22, 2024 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a biotechnology company developing therapie

    3/22/24 7:00:00 AM ET
    $ANTX
    $VBIV
    $VIR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $ANTX
    Leadership Updates

    Live Leadership Updates

    View All

    Brii Biosciences Provides Latest Clinical Development and Corporate Updates

    Company extends BRII-179 license to global rights and introduces preventive vaccine, PreHevbri® in Greater China and Asia Pacific markets New data from BRII-835 + PEG-IFN-α study have demonstrated that robust anti-HBs antibody responses at the end of treatment are associated with sustained HBsAg loss 24 weeks post treatment Company owns exclusive global rights of BRII-693 in development for difficult-to-treat carbapenem-resistant Gram-negative bacterial infections Dr. David Margolis appointed as Chief Medical Officer to lead organization's late-stage clinical programs towards commercialization DURHAM, N.C. and BEIJING, July 5, 2023 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the

    7/5/23 7:18:00 PM ET
    $ANTX
    $VBIV
    $VIR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    AN2 Therapeutics Appoints Maggie FitzPatrick to Its Board of Directors

    AN2 Therapeutics, Inc., (NASDAQ:ANTX) a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced the appointment of Maggie FitzPatrick to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220509005229/en/Maggie FitzPatrick, Board of Directors, AN2 Therapeutics, Inc. (Photo: Business Wire) Maggie FitzPatrick is a highly accomplished corporate affairs executive who has led global communications and public affairs at leading healthcare companies, including Johnson & Johnson and Cigna. "As a recognized leader in the a

    5/9/22 7:00:00 AM ET
    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by AN2 Therapeutics Inc.

    SC 13G/A - AN2 Therapeutics, Inc. (0001880438) (Subject)

    11/14/24 4:29:18 PM ET
    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by AN2 Therapeutics Inc.

    SC 13G/A - AN2 Therapeutics, Inc. (0001880438) (Subject)

    11/14/24 4:16:45 PM ET
    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by AN2 Therapeutics Inc.

    SC 13G/A - AN2 Therapeutics, Inc. (0001880438) (Subject)

    11/13/24 4:25:27 PM ET
    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care